New OrbiMed-backed biotech aims to replicate Vertex's wildly successful cystic fibrosis pills in other diseases
A new biotech aiming to tackle protein misfolding has landed a substantial Series A from some blue-chip investors.
Congruence Therapeutics burst onto the scene Tuesday with a $50 million round, including funds from OrbiMed. The biotech will use the money to advance its platform and move some of its programs forward, CEO Clarissa Desjardins told Endpoints News.
Tuesday’s round was led by Amplitude Ventures and Fonds de solidarité FTQ, a public development fund in Quebec, Canada.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.